BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
UBS
QuintilesIMS
Cerilliant
AstraZeneca
Accenture
Fish and Richardson
Boehringer Ingelheim
Cantor Fitzgerald

Generated: January 20, 2018

DrugPatentWatch Database Preview

Iloperidone - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for iloperidone and what is the scope of iloperidone freedom to operate?

Iloperidone
is the generic ingredient in two branded drugs marketed by Vanda Pharms Inc and Inventia Hlthcare, and is included in two NDAs. There are ten patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Iloperidone has one hundred and seventy-nine patent family members in thirty-one countries.

There are eight drug master file entries for iloperidone. Three suppliers are listed for this compound.
Summary for iloperidone
Pharmacology for iloperidone

US Patents and Regulatory Information for iloperidone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Inventia Hlthcare ILOPERIDONE iloperidone TABLET;ORAL 207231-001 Nov 28, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-007 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-006 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for iloperidone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-007 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 ➤ Subscribe ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-006 May 6, 2009 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for iloperidone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,140,345 1-(aryloxyalkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics ➤ Subscribe
RE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics ➤ Subscribe
5,612,342 United States Patent: 5612342   ( 1 ➤ Subscribe
6,420,390 Heteroarylpiperidines and their use as antipsychotics ➤ Subscribe
5,556,858 Cis-2-[(4-heteroaryl-1-piperazinyl)alkyl] hexahydro-1H-isoindole-1,3 (2H)-diones and related compounds and their therapeutic utility ➤ Subscribe
RE39265 Heteroarylpiperidines, and their use as antipsychotics and analgetics ➤ Subscribe
5,571,803 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics ➤ Subscribe
5,580,886 Cis-2-[(4-heteroaryl-1 -piperidinyl)alkyl]hexahydro-1H-isoindole-1,3(2H)-diones and related compounds and their therapeutic utility ➤ Subscribe
5,364,866 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics ➤ Subscribe
5,580,891 N-[heteroaryl-1-pyrrolidinyl)alkyl]-2-benoxazolinones and related compounds and their therapeutic utility ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for iloperidone

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
US Army
McKinsey
Baxter
Queensland Health
Cipla
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot